ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Clinical trials for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new combo boost remission in tough leukemia?
Disease control OngoingThis study tests whether adding the drug pomalidomide to standard chemotherapy helps people with a certain type of acute myeloid leukemia (AML) that is linked to prior blood disorders or cancer treatment. About 50 adults with newly diagnosed AML will be randomly assigned to get e…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
Immunotherapy boosts standard chemo to wipe out hidden leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The goal …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
Immunotherapy boosts standard AML treatment in older patients
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) helps older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer returning. About 60 participants who are not e…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for people with acute myeloid leukemia (AML). It includes older adults who cannot have standard treatment or those with relapsed or hard-to-treat AML. The goal is to find a to…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Targeted drug shows promise for Hard-to-Treat blood cancers with IDH mutation
Disease control OngoingThis study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC